

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jul 2026

Efficacy of topical terbinafine and ketoconazole in pityriasis versicolor

Protocol summary

Summary

The main aim of this study: efficacy of topical terbinafine and ketoconazole in pityriasis versicolor (rct -single blind) Inclusion criteria are: KOH positive ; involvement of less than 10% of the body surface by the lesions. Exclusion criteria are: Extensive involvement of the skin ; topical or systemic antifungal therapy; and use of steroid or antibiotic within the last month before starting the study The samples will be examined microscopically for the presence of mycelium by a pathologist if the smears are positive for mycelium. Sample size in study 100 patients they will be allocated to 2 groups randomly. Intervention group will use t terbinafin hydrochloride 1% cream.the creams are used topically twice a day for 2 weeks. . determined clinically based on observation of signs and symptoms. Itching, scaling and redness are the clinical

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201107184808N4**

Registration date: **2011-11-13, 1390/08/22**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2011-11-13, 1390/08/22

Registrant information

Name

Mozhdeh Zarei

Name of organization / entity

Kurdistan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 87 1613 1278

Email address

mozh.zarei@muk.ac.ir

Recruitment status

Recruitment complete

Funding source

Kurdistan University of Medical Sciences

Expected recruitment start date

2010-04-19, 1389/01/30

Expected recruitment end date

2011-10-23, 1390/08/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy of topical terbinafine and ketoconazole in pityriasis versicolor

Public title

Versicolor Treatment

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria are:Age above 14 years; KOH positive ; involvement of less than 10% of the body surface by the lesions. Exclusion criteria are:Extensive involvement of the skin ; topical or systemic antifungal therapy; and use of steroid or antibiotic within the last month before starting the study;pregnancy or likelihood of pregnancy; lactation and the patients who are not cooperative

Age

From **14 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size
Target sample size: **100**

Randomization (investigator's opinion)
Randomized

Randomization description

Blinding (investigator's opinion)
Single blinded

Blinding description

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
KURDISTAN University of Medical Sciences
Street address
KURDISTAN University of Medical Sciences
City
SANANDAJ
Postal code
6617711446
Approval date
2011-03-19, 1389/12/28
Ethics committee reference number
14/1203 28/12/1389

Health conditions studied

1

Description of health condition studied
versicolor
ICD-10 code
B36.0
ICD-10 code description
Pityriasis versicolor

Primary outcomes

1

Description
PTRIASIS versicolor
Timepoint
After completion of the treatment course the patients will be requested to refer for follow up after 1 weeks, one month and two months of treatment or in case of recurrence of the lesions.
Method of measurement
Skin smears are taken by a scalpel or a tape and will be examined by a pathologist for the presence of mycelium.

The patients with positive smears will enter into the study.

Secondary outcomes

1

Description
LOCAL complications
Timepoint
after 2 weeks, one month and two months of treatment
Method of measurement
by a physician or patient self-report

Intervention groups

1

Description
CONTROL: ketoconazol 2% cream .the creams are used topically twice a day for 2 weeks.
Category
Treatment - Drugs

2

Description
INTERVENTIONAL:terbinafin hydrochloride 1% cream.the creams are used topically twice a day for 2 weeks.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Doctor's office . BESATHOSPITAL
Full name of responsible person
DR.FAROKH RAD
Street address
KURDISTAN University of Medical Sciences
City
SANANDAJ

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
KURDISTAN University of Medical Sciences
Full name of responsible person
MOZHDEH ZAREI
Street address
KURDISTAN University of Medical Sciences
City
SANANDAJ
Grant name
Grant code / Reference number

25000000 R
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
KURDISTAN University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity
MEDICAL UNIVERSITY OF KURDISTAN
Full name of responsible person
DR FAROKH RAD
Position
dermatologist
Other areas of specialty/work
Street address
KURDISTAN University of Medical Sciences
City
SANANDAJ
Postal code
6617711446
Phone
+98 87 1613 1278
Fax
+98 87 1666 5354
Email
MOZH.ZAREI@MUK.AC.IR
Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity
KURDISTAN University of Medical Sciences
Full name of responsible person
DR Farokh Rad
Position
dermatologist
Other areas of specialty/work
Street address

KURDISTAN province, Sanandaj, PASDARAN avenue,
KURDISTAN University of Medical Sciences

City
SANANDAJ
Postal code
6617711446
Phone
+98 87 1613 1278
Fax
+98 87 1666 5354
Email
mozh.zarei@yahoo.com
Web page address

Person responsible for updating data

Contact

Name of organization / entity
Medical University OF KURDISTAN
Full name of responsible person
DR Farokh Rad
Position
dermatologist
Other areas of specialty/work
Street address
KURDISTAN University of Medical Sciences
City
Sanandaj
Postal code
6617711446
Phone
+98 87 1613 1278
Fax
+98 87 1666 5354
Email
MZH.ZAREI@MUK.AC.IR
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty